New capabilities to be launched on March 25<\/p>\n
Unique technology bolsters BullFrog AI\u2019s end-to-end AI intelligence workflow with a scenario-based decision engine<\/p>\n
Advances current AI decision tools by clearly defining clinical trial strategies and building diversified, risk-balanced R&D portfolios<\/p>\n
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (\u201cBullFrog AI\u201d or the \u201cCompany\u201d), a technology company using artificial intelligence (\u201cAI\u201d) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design.<\/p>\n
The new AI capability advances the Company\u2019s end-to-end intelligence workflow by adding a strategic decision layer on top of existing platforms bfPREP and bfLEAP\u00ae. Unlike traditional portfolio tools that collapse complex judgments into single scores and fixed weightings, the upcoming offering evaluates options using proprietary algorithms and methodologies revealing which programs are robust winners and which succeed only under narrow conditions.<\/p>\n
Key capabilities include:<\/p>\n
Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores<\/p>\n
Tests portfolio decisions against multiple explicit scenarios (e.g., capital-constrained, platform-building, US-first, global)<\/p>\n
Identifies options that perform well across strategic futures<\/p>\n
Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation<\/p>\n
\u201cEach year, more than $200 billion is spent by life science and pharmaceutical companies on research and development, with very low returns given an estimated 90% clinical trial failure rate. While AI adoption in drug discovery has accelerated, strategic portfolio decisions still rely largely on manual scoring and spreadsheet-based tools that force rigid rankings on fundamentally comparative judgments,\u201d said BullFrog AI Founder and CEO Vin Singh. \u201cOur new capability takes a different approach by treating strategic scenarios as first-class inputs. It surfaces robust recommendations and highlights options that perform well under multiple strategic futures\u2014enabling clear R&D strategies and the construction of diversified, risk-balanced R&D portfolios. To our knowledge, no other solution in the world can offer this capability.\u201d<\/p>\n
Please visit the BullFrog AI\u00a0website\u00a0for updates on the new product launch.The post BullFrog AI to Unveil New Precision AI Capability first appeared on AI-Tech Park.<\/p>\n","protected":false},"excerpt":{"rendered":"
BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (\u201cBullFrog AI\u201d or the \u201cCompany\u201d), a technology company using artificial intelligence (\u201cAI\u201d) and machine learning to turn complex biomedical data into actionable insights, announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. The new…<\/p>\n
The post BullFrog AI to Unveil New Precision AI Capability<\/a> first appeared on AI-Tech Park<\/a>.<\/p>\n<\/div>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-container-style":"default","site-container-layout":"default","site-sidebar-layout":"default","disable-article-header":"default","disable-site-header":"default","disable-site-footer":"default","disable-content-area-spacing":"default","footnotes":""},"categories":[1,38],"tags":[3],"class_list":["post-1145","post","type-post","status-publish","format-standard","hentry","category-ai-and-ml","category-machine-learning","tag-ai"],"yoast_head":"\n